AI-powered drug developer company Unravel Biosciences has secured the Orphan Drug Designation from the FDA for RVL-001 (Vorinostat) to treat Rett Syndrome, a rare genetic neurological disorder.
RVL-001 was developed through Unravel's BioNAV drug discovery platform and will proceed toward clinical testing and manufacturing for upcoming clinical trials.
Unravel Biosciences is a biotechnology company specializing in developing therapeutics for complex disorders. The company’s technology includes integrating AI with biology computation and rapid in vivo screening to identify and validate new drug targets. Unravel’s proprietary BioNAV platform analyzes RNA data from patients to predict therapeutic molecules with increased accuracy and speed.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.